Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Theriva Biologics Inc

TOVX ✓ COMPLIANT ☆ Track — members

NYSE MKT · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$0.23

▼ -4.46%

Market Cap $0.00 · Vol 18.82K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$0.00

Micro Cap

Div Yield

N/A

EPS Growth

+88.70%

YoY

RSI (14)

41.80

Momentum

Beta

1.19

vs Market

52W High

$0.86

73.92% below

52W Low

$0.16

38.01% above

Volume

18.82K

Avg 27.62K

P/B

0.49

Price-to-book

ROE

N/A

Return on equity

Free Float

98.37%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Theriva Biologics Inc (TOVX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does TOVX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-8.90%

-1.27%

-23.44%

+28.48%

YTD

+6.99%

-45.67%

-98.43%

-99.81%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-23,739,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-64.52% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	0.49
P/FCF	N/A
EPS Growth	+88.70%
Outstanding Shares	45.89M

Technical Indicators

50-Day SMA	$0.23
200-Day SMA	$0.24
RSI (14)	41.80
Beta	1.19
52-Week High	$0.86
52-Week Low	$0.16

Volume Today	18.82K
Avg Daily Volume (30D)	27.62K
Relative Volume	0.68x
Volatility (10D)	37.18
Volatility (30D)	43.02
Free Float	98.37%

Analyst Consensus

BUY

Current Price $0.23

Mean Target $2.50

52W Low$0.16 52W High$0.86

Current

Target

$0.16 $0.86

Current Analyst target

+1,010.62% upside potential · 2 analysts

Identifiers

ExchangeNYSE MKT

FIGIBBG001S77L07

ISINUS87164U5083

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 10, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

SER Serina Therapeutics, Inc. -4.08% BYSI Beyondspring Inc -1.25% OGEN Oragenics Inc -2.28% BCDA BioCardia Inc +3.36% CALC CalciMedica Inc -1.00%

Company Profile

Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company is advancing a new oncolytic adenovirus platform. The Company’s candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a physical and immunosuppressive barrier to cancer treatment; SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci), and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.